Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences
Solid Biosciences (Nasdaq: SLDB) announced its participation in two significant conferences focusing on Duchenne muscular dystrophy therapies.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Solid Biosciences (Nasdaq: SLDB) announced its participation in two significant conferences focusing on Duchenne muscular dystrophy therapies. At the PPMD 2022 Annual Conference from June 23-26 in Scottsdale, AZ, Chief Scientific Officer Carl Morris will discuss gene therapy approaches on June 24 at 11:30 a.m. EDT. Subsequently, at the ICNMD 2022 in Brussels from July 5-9, Perry Shieh will present selected abstracts on July 7 at 10:30 a.m. ET. Solid Biosciences is dedicated to developing innovative treatments like SGT-001 and SGT-003 to address Duchenne at its genetic source.
Details
News Market Reaction – SLDB
The recorded move for SLDB in the trading session of this news was +8.52%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scientific and patient advocacy conferences:
PPMD 2022 Annual Conference – June 23-26, 2022, Scottsdale, AZ
Carl Morris, Ph.D., Chief Scientific Officer at Solid Biosciences, will participate in the Gene Therapy Approaches to Replace or Restore Dystrophin session on Friday, June 24, at 11:30 a.m. EDT / 8:30 a.m. MST.
Event and registration information is available at:
https://www.parentprojectmd.org/events/ppmds-2022-annual-conference/
ICNMD 2022 | 17th International Congress on Neuromuscular Diseases – July 5-9, 2022, Brussels, BE
Perry Shieh, M.D., Ph. D. Professor of Neurology and Pediatrics at the University of California, Los Angeles, and an IGNITE DMD investigator, will participate in the PS03: Selected Abstracts for Oral Presentation session on Thursday, July 7, at 10:30 a.m. ET / 4:30 p.m. CEST.
Event and registration information is available at: https://icnmd.org/registration2022/
About Solid Biosciences
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001, as well as our recently announced next-generation gene therapy candidate, SGT-003. For more information, please visit www.solidbio.com.
Investor Contact:
David Carey
FINN Partners
212-867-1768
David.Carey@finnpartners.com
Caitlin Lowie
Solid Biosciences
607-423-3219
CLowie@solidbio.com
Media Contact:
Erich Sandoval
FINN Partners
917-497-2867
Erich.Sandoval@finnpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.